APA 6th Edition Vladareanu, A., Popov, V., Vasilache, V., Marinescu, C., Bumbea, H., Zvanca, M., ... Vladareanu, R. (2008). LEUKEMIA AND PREGNANCY. NO LONGER A DANGEROUS LIAISON? – CASE REPORT AND REVIEW OF LITERATURE. Gynaecologia et perinatologia, 17 (2), 94-100. Preuzeto s https://hrcak.srce.hr/62101
MLA 8th Edition Vladareanu, Ana-Maria, et al. "LEUKEMIA AND PREGNANCY. NO LONGER A DANGEROUS LIAISON? – CASE REPORT AND REVIEW OF LITERATURE." Gynaecologia et perinatologia, vol. 17, br. 2, 2008, str. 94-100. https://hrcak.srce.hr/62101. Citirano 20.01.2020.
Chicago 17th Edition Vladareanu, Ana-Maria, Viola Popov, Veronica Vasilache, Cristina Marinescu, Horia Bumbea, MOna Zvanca, Diana Cisleanu, et al. "LEUKEMIA AND PREGNANCY. NO LONGER A DANGEROUS LIAISON? – CASE REPORT AND REVIEW OF LITERATURE." Gynaecologia et perinatologia 17, br. 2 (2008): 94-100. https://hrcak.srce.hr/62101
Harvard Vladareanu, A., et al. (2008). 'LEUKEMIA AND PREGNANCY. NO LONGER A DANGEROUS LIAISON? – CASE REPORT AND REVIEW OF LITERATURE', Gynaecologia et perinatologia, 17(2), str. 94-100. Preuzeto s: https://hrcak.srce.hr/62101 (Datum pristupa: 20.01.2020.)
Vancouver Vladareanu A, Popov V, Vasilache V, Marinescu C, Bumbea H, Zvanca M i sur. LEUKEMIA AND PREGNANCY. NO LONGER A DANGEROUS LIAISON? – CASE REPORT AND REVIEW OF LITERATURE. Gynaecologia et perinatologia [Internet]. 2008 [pristupljeno 20.01.2020.];17(2):94-100. Dostupno na: https://hrcak.srce.hr/62101
IEEE A. Vladareanu, et al., "LEUKEMIA AND PREGNANCY. NO LONGER A DANGEROUS LIAISON? – CASE REPORT AND REVIEW OF LITERATURE", Gynaecologia et perinatologia, vol.17, br. 2, str. 94-100, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/62101. [Citirano: 20.01.2020.]
Sažetak SUMMARY. Purpose. Even though there are no solid data regarding chemotherapy treated leukemia during pregnancy, the results based on short series reports show that the management of such condition can be safely achieved during the second and third trimester. We present three personal cases of pregnant women treated with cytostatic agents, two of them accidentally receiving complete chemotherapy during the entire pregnancy without malformative consequences. First case. A 19 yrs old woman diagnosed with chronic myeloid leukemia who conceived spontaneously and mistook the pregnancy signs for a relapse of the disease. During the pregnancy she continued the treatment, receiving until the fifth month an association of Hydroxyurea and alfa-interferon and afterwards switched to Imatinib until term. She presented at 38–39 weeks and delivered by cesarean section a little girl of 3510 g in a perfect state of health. The blood count of both mother and child were normal. Second case. A similar situation in a young woman with lymphoblastic acute leukemia under treatment with Vincristin, Methotrexat, Purinethol. She presented in advanced spontaneous labour at 33–34 weeks and delivered a little girl of 1700 g without malformative signs and normal blood count. Third case. A 17 years old girl who was diagnosed with acute myeloid leukemia at 29 weeks pregnancy. She received induction chemotherapy with Ara-C, due to the significant bone marrow infiltrate and disease induced disseminated intravascular coagulopathy. She presented premature uterine contractions at 32 weeks and delivered by cesarean section a premature boy of 1750g with Apgar score 8. The infant did not present any malformation (by clinical and ultrasound examination) and the blood count was normal.
The studies have shown so far that in the case of chronic myeloid leukemia, the treatment with Imatinib was associated with 50% apparently normal live infants and that chemotherapy for acute leukemia during the second or third trimester may not require termination of pregnancy, because both remission and delivery of a normal infant are likely to be obtained.